KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacira BioSciences (PCRX) EBITDA Margin (2016 - 2026)

Pacira BioSciences has reported EBITDA Margin over the past 17 years, most recently at 3.89% for Q1 2026.

  • For Q1 2026, EBITDA Margin rose 271.0% year-over-year to 3.89%; the TTM value through Mar 2026 reached 3.28%, up 1532.0%, while the annual FY2025 figure was 2.64%, 1311.0% up from the prior year.
  • EBITDA Margin for Q1 2026 was 3.89% at Pacira BioSciences, up from 1.19% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 23.53% in Q2 2023 and troughed at 82.77% in Q3 2024.
  • A 5-year average of 3.74% and a median of 7.91% in 2024 define the central range for EBITDA Margin.
  • Biggest five-year swings in EBITDA Margin: plummeted -9358bps in 2024 and later surged 8631bps in 2025.
  • Year by year, EBITDA Margin stood at 2.06% in 2022, then surged by 787bps to 18.3% in 2023, then decreased by -28bps to 13.19% in 2024, then plummeted by -91bps to 1.19% in 2025, then surged by 227bps to 3.89% in 2026.
  • Business Quant data shows EBITDA Margin for PCRX at 3.89% in Q1 2026, 1.19% in Q4 2025, and 3.54% in Q3 2025.